Under the terms of the sales and marketing agreement, Patheon will promote BSP’s cytotoxic manufacturing capacity and development services. Aldo Braca, president of Patheon Europe will be president and CEO of BSP Pharmaceuticals.
Patheon is in the process of identifying a successor to Mr Braca and for a transitional period, Mr Braca will fill both roles.
Wes Wheeler, president and CEO of Patheon, said: “With these agreements in place, Patheon can now offer its clients a complete suite of services – which now includes cytotoxics – in contract manufacturing and formulation development.”